Rhizen Pharmaceuticals S.A. to present Phase 1 clinical and additional preclinical data of RP6530 (dual PI3K delta/gamma inhibitor) in hematological malignancies

La Chaux-de-Fonds, Switzerland, Dec. 3, 2014 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. announces Phase 1 clinical and additional preclinical data presentations for RP6530, a novel dual PI3K delta/gamma inhibitor in hematological malignancies

--- Two posters to be presented at the 56th American Society of Hematology (ASH) Annual Meeting & Exposition, December 6-9, 2014, Moscone Center, San Francisco, CA

**Phase 1 clinical study:**
--- In the ongoing Phase 1 study in Europe, RP6530 demonstrated excellent safety across four dose levels; 25 mg BID, 50 mg BID, 100 mg BID and 200 mg BID. No increase in ALT/AST, colitis, pneumonia, or drug related neutropenia reported among treated patients
--- Clinical efficacy was manifested by a significant reduction in peripheral blood cell pAKT expression levels across all doses. MTD has not been reached and dose escalation continues at 400 mg BID
--- Despite the heavy pre-treatment (median 5) and disease burden, oral administration of RP6530 controlled tumor progression in 75% patients

**Preclinical data in combination with ibrutinib (IMBRUVICA®) in DLBCL cell lines:**
--- Data demonstrated single-agent activity of RP6530 as well as synergism with ibrutinib in DLBCL representative cell lines
--- Addition of RP6530 overcomes ibrutinib resistance in DLBCL cells in vitro. Combining RP6530 with ibrutinib therefore appears to be a potential therapeutic approach aimed at circumventing resistance emerging in patients after prolonged ibrutinib therapy

**About RP6530:**

RP6530 is a highly selective and orally active dual PI3K delta/gamma inhibitor with efficient translation of activity through enzyme, cell, and whole blood-based studies. Besides inhibiting growth of immortalized cancerous cell lines and primary patient leukemic/lymphoma cells, RP6530 plays a significant role in modulation of tumor microenvironment at clinically achievable concentrations. A Phase 1 dose-escalation trial evaluating the safety and efficacy of RP6530 in patients with relapsed/refractory hematological malignancies is currently ongoing (ClinicalTrials.gov Identifier: NCT02017613).
Details of the poster presentations:

-- Poster Title: A Phase 1 Dose Escalation Study of RP6530, a Novel, Dual PI3K-γδ Inhibitor, for Patients with Relapsed or Refractory Hematologic Malignancies
  • Poster Session: 623. Lymphoma: Chemotherapy, excluding Pre-Clinical Models: Poster II
  • Presentation Date: 07 December 2014
  • Time: 6:00 – 8:00 PM Pacific Standard Time
  • Poster Board Number: 3043
  • Place: West Building, Level 1 (Moscone Center)

-- Poster Title: Addition of RP6530, a Dual PI3K δ/γ Inhibitor, Overcomes Ibrutinib Resistance in DLBCL Cells in Vitro
  • Poster Session: 625. Lymphoma: Pre-Clinical – Chemotherapy and Biologic Agents: Poster III
  • Presentation Date: 08 December 2014
  • Time: 6:00 – 8:00 PM Pacific Standard Time
  • Poster Board Number: 4497
  • Place: West Building, Level 1 (Moscone Center)

About Rhizen Pharmaceuticals S.A.:

Rhizen Pharmaceuticals is an innovative, clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of cancer, immune and metabolic disorders. Since its establishment in 2008, Rhizen has created a diverse pipeline of proprietary drug candidates targeting several cancers and immune associated cellular pathways. Rhizen is headquartered in La-Chaux-de-Fonds, Switzerland. For additional information, please visit Rhizen’s website, [www.rhizen.com](http://www.rhizen.com).

Contact: Kumar V. Penmetsa, Ph.D.
Vice President, Corporate Development
Rhizen Pharmaceuticals S.A.
Telephone: +1-267-207-5707
Email: kvp@rhizen.com